<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02538926</url>
  </required_header>
  <id_info>
    <org_study_id>9459</org_study_id>
    <secondary_id>NCI-2015-01402</secondary_id>
    <secondary_id>CC9459</secondary_id>
    <secondary_id>9459</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT02538926</nct_id>
  </id_info>
  <brief_title>Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma</brief_title>
  <official_title>A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Asparaginase (DA-EPOCH-A) for Adults With Acute Lymphoblastic Leukemia/Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well etoposide, prednisone, vincristine sulfate,
      cyclophosphamide, and doxorubicin hydrochloride with asparaginase work in treating patients
      with acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such
      as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin
      hydrochloride, work in different ways to stop the growth of cancer cells, either by killing
      the cells, by stopping them from dividing, or by stopping them from spreading. Asparaginase
      breaks down the amino acid asparagine and may block the growth of tumor cells that need
      asparagine to grow. Giving combination chemotherapy with asparaginase may work better in
      treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the efficacy of dose-adjusted etoposide, prednisone, vincristine sulfate,
      cyclophosphamide, and doxorubicin hydrochloride plus asparaginase (DA-EPOCH-A) in adults with
      acute lymphoblastic leukemia/lymphoma (ALL).

      SECONDARY OBJECTIVES:

      I. To evaluate the safety and feasibility of this regimen.

      OUTLINE:

      Patients receive etoposide, doxorubicin hydrochloride, and vincristine sulfate intravenously
      (IV) continuously over days 1-4, cyclophosphamide IV over 1 hour on day 5, and prednisone
      orally (PO) twice daily (BID) on days 1-5. Patients also receive asparaginase intramuscularly
      (IM) or IV over 1-2 hours every 2-3 days, beginning day 7 of each course. Patients who are
      cluster of differentiation (CD)20 positive and Philadelphia chromosome negative also receive
      rituximab IV on day 1 or 5. Patients who are Philadelphia chromosome positive also receive
      imatinib mesylate PO on days 1-14. Treatment repeats every 21 days for up to 8 courses in the
      absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 2 years and
      then every 6 months for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete minimal residual disease response rate</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>A Simon two-stage optimum design will be used to define success of this treatment in the two subgroups of patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (complete response + partial response)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>A Simon two-stage optimum design will be used to define success of this treatment in the two subgroups of patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From time of initiation of study therapy to up to 5 years</time_frame>
    <description>A Simon two-stage optimum design will be used to define success of this treatment in the two subgroups of patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From time of initiation of study therapy to up to 5 years</time_frame>
    <description>A Simon two-stage optimum design will be used to define success of this treatment in the two subgroups of patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, graded using the National Cancer Institute Common Terminology Criteria for Adverse Events</measure>
    <time_frame>Up to 30 days post-treatment, or until patient receives an alternative anti-cancer therapy, whichever date comes first</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">71</enrollment>
  <condition>B Acute Lymphoblastic Leukemia</condition>
  <condition>B Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent B Lymphoblastic Lymphoma</condition>
  <condition>Recurrent T Lymphoblastic Leukemia/Lymphoma</condition>
  <condition>Refractory B Lymphoblastic Lymphoma</condition>
  <condition>Refractory T Lymphoblastic Lymphoma</condition>
  <condition>T Acute Lymphoblastic Leukemia</condition>
  <condition>T Lymphoblastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive etoposide, doxorubicin hydrochloride, and vincristine sulfate IV continuously over days 1-4, cyclophosphamide IV over 1 hour on day 5, and prednisone PO BID on days 1-5. Patients also receive asparaginase IM or IV over 1-2 hours every 2-3 days, beginning day 7 of each course. Patients who are CD20 positive and Philadelphia chromosome negative also receive rituximab IV on day 1 or 5. Patients who are Philadelphia chromosome positive also receive imatinib mesylate PO on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asparaginase</intervention_name>
    <description>Given IM or IV</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <other_name>ASP-1</other_name>
    <other_name>Asparaginase II</other_name>
    <other_name>Asparaginase-E.Coli</other_name>
    <other_name>Colaspase</other_name>
    <other_name>Elspar</other_name>
    <other_name>Kidrolase</other_name>
    <other_name>L-Asnase</other_name>
    <other_name>L-ASP</other_name>
    <other_name>L-Asparaginase</other_name>
    <other_name>L-Asparagine Amidohydrolase</other_name>
    <other_name>Laspar</other_name>
    <other_name>Lcf-ASP</other_name>
    <other_name>Leucogen</other_name>
    <other_name>Leunase</other_name>
    <other_name>MK-965</other_name>
    <other_name>Paronal</other_name>
    <other_name>Re-82-TAD-15</other_name>
    <other_name>Serasa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib Mesylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <other_name>CGP 57148</other_name>
    <other_name>CGP57148B</other_name>
    <other_name>Gleevec</other_name>
    <other_name>Glivec</other_name>
    <other_name>STI 571</other_name>
    <other_name>STI-571</other_name>
    <other_name>STI571</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>RTXM83</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <other_name>Kyocristine</other_name>
    <other_name>Leurocristine Sulfate</other_name>
    <other_name>Leurocristine, sulfate</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>Vincosid</other_name>
    <other_name>Vincrex</other_name>
    <other_name>Vincristine, sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a confirmed diagnosis of either B- or T-cell acute lymphoblastic
             leukemia or lymphoblastic lymphoma that is either:

               -  Arm A: Initially diagnosed at age 40 or later, OR

               -  Arm B: Relapsed after or failed to respond to &gt;= 1 previous chemotherapy regimen

          -  The regimen under study must constitute a reasonable therapeutic option

          -  Presence of &gt;= 5% abnormal blasts in the bone marrow

          -  Patients with prior allogeneic hematopoietic cell transplantation (HCT) must be at
             least 90 days post-HCT and must be on =&lt; 20 mg of prednisone (or equivalent dose of an
             alternative corticosteroid) for treatment/prevention of graft-vs-host disease

          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal (ULN; unless attributable
             to Gilbert's disease or other causes of inherited indirect hyperbilirubinemia, at
             which point total bilirubin must be =&lt; 2.5 x ULN)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt; 3.0 x institutional ULN

          -  Note: Patients with liver test abnormalities attributable to hepatic involvement by
             ALL will be permitted if the total bilirubin is =&lt; 3.0 x ULN and ALT/AST are =&lt; 5.0 x
             ULN

          -  Creatinine =&lt; 1.5 mg/dL; however, patients with a creatinine &gt; 1.5 mg/dL but with a
             calculated creatinine clearance of &gt; 60 ml/min, as measured by the Modification of
             Diet in Renal Disease (MDRD) equation, will be eligible

          -  Measurement of left ventricular ejection fraction (LVEF) should be performed in
             patients with prior anthracycline exposure or known history of arrhythmia or
             structural heart disease; in these cases, LVEF must be &gt;= 40%

          -  As patients with ALL frequently have cytopenias, no hematologic parameters will be
             required for enrollment or to receive the first cycle of treatment; however, adequate
             recovery of blood counts will be required to receive subsequent cycles

          -  Per good clinical practice, any toxicity related to prior therapies that, in the
             opinion of the investigator, would potentially be worsened with DA-EPOCH-A +/-
             imatinib (imatinib mesylate) +/- rituximab, should be resolved to grade 1 or less

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

          -  Women of childbearing potential must have a negative pregnancy test and must agree to
             the use of effective contraception while on treatment; men must also agree to the use
             of effective contraception while on treatment

          -  Ability to give informed consent and comply with the protocol

          -  Anticipated survival of at least 3 months

        Exclusion Criteria:

          -  Patients with Burkitt lymphoma/leukemia

          -  Patients must not have received chemotherapy within 14 days of enrollment, with the
             two following exceptions:

               -  Routine systemic maintenance therapy (e.g., Abelson murine leukemia viral
                  oncogene homolog 1 [ABL] kinase inhibitor, methotrexate, 6-mercaptopurine,
                  vincristine, etc.) and intrathecal/intraventricular therapy

               -  Systemic therapy for the acute management of hyperleukocytosis or acute symptoms
                  (e.g., corticosteroids, cytarabine, etc.)

          -  May not have prior malignancies unless the expected survival is at least 2 years

          -  For patients with Philadelphia chromosome positive (Ph+) ALL, they must not have
             progressed within 3 months of receiving imatinib or have a documented ABL kinase
             mutation known to confer resistance to imatinib (e.g., T315I)

          -  Patients with persistent grade 2 or higher peripheral sensory or motor neuropathy of
             any cause

          -  Patients with isolated extramedullary disease or with parenchymal central nervous
             system (CNS) disease

          -  Known hypersensitivity or intolerance to any of the agents under investigation

          -  Human immunodeficiency virus (HIV) positive or evidence of infection with hepatitis B
             or C virus, as defined by any of the following criteria (if patients have not
             previously been tested for the following, these will be conducted during screening):

               -  HIV antibody positive

               -  Hepatitis B surface antigen or core antibody positive

               -  Hepatitis C antibody positive

          -  Other medical or psychiatric conditions that in the opinion of the investigator would
             preclude safe participation in the protocol

          -  May not be pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Cassaday</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ryan D. Cassaday</last_name>
    </contact>
    <investigator>
      <last_name>Ryan D. Cassaday</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>August 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Cortisone acetate</mesh_term>
    <mesh_term>Cortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

